Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Multiple Myeloma 52Leukemia, Myeloid, Acute 49Lymphoma, Non-Hodgkin 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Lymphoma 37Leukemia 35Hodgkin Disease 35Myelodysplastic Syndromes 33Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Burkitt Lymphoma 17Lymphoma, Follicular 12Hematologic Neoplasms 12Neoplasms, Plasma Cell 11Congenital Abnormalities 11Lymphoma, B-Cell, Marginal Zone 10Leukemia, Biphenotypic, Acute 9Breast Neoplasms 9Myeloproliferative Disorders 8Lymphoma, Large-Cell, Immunoblastic 8Anemia, Refractory, with Excess of Blasts 8Recurrence 7Leukemia, Myelomonocytic, Juvenile 7Leukemia, Myelomonocytic, Chronic 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Graft vs Host Disease 6Sarcoma 5

Interventions

pegfilgrastim 4balugrastim 2NPI 2358 2Granulocyte Colony-Stimulating Factor 2Drug Therapy 2Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Chemotherapy-induced Neutropenia × Granulocyte Colony-Stimulating Factor × Clear all
NCT03102606 2024-08-29

Protective-1

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
105 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT04345900 2024-05-16

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
55 enrolled 21 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡